Scott Becker

And so this is today's tribute and shout out to the greatest person I work with today.

Love working with her.

The very best.

Happy birthday to Chanel Bunger, and you are a tremendous, tremendous professional, as good as they come.

Thank you very much.

And thank you all for listening to the Becker Business Podcast, the Becker Private Equity Podcast.

We love what we do.

We hope you enjoy it too.

Thank you very much.

This is Scott Becker with the Becker Business Podcast, the Becker Private Equity Podcast.

Today's discussion is Novo Nordisk and excess profits.

And that's what's happened with Novo Nordisk.

They've cut their expected full-year sales growth to 8% to 14%, down from 20% or so.

Their stock has fallen about 20% today.

It's down more than 20% today.

Their main weight loss drug is Letgovi, but they're basically seeing themselves splash their forecast and sales and profit forecast for that.

It's another example that when you're going after stuff and you've got this great excess profits, that other parties are going to come after you and try and eat into that as well.

They're seeing a lot of that.

They're aggressively cutting their profits.

forecast, the stock is down more than 50% over the past year as they faced increased competition from others like hims and hers, Eli Lilly and others.